As prostate cancer progresses from hormone sensitive to hormonerefractory, the circulating concentrations of IL-6 in the serum of patients increase (Fearon et al, 1991; Drachenberg et al, 1999; Heinrich et al, 2003). Here, IL6 is linked to Familial prostate cancer.